A D Michel1, E Fonfria. 1. Neurology & GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Limited, New Frontiers Science Park, Harlow, Essex, UK. adm7393@gsk.com
Abstract
BACKGROUND AND PURPOSE: The P2X(7) receptor exhibits a high degree of plasticity with agonist potency increasing after prolonged receptor activation. In this study we investigated the ability of lipids to modulate agonist potency at P2X(7) receptors. EXPERIMENTAL APPROACH: A variety of lipids, including lysophosphatidylcholine, sphingosylphosphorylcholine and hexadecylphosphorylcholine were studied for their effect on P2X(7) receptor-stimulated ethidium bromide accumulation in cells expressing human recombinant P2X(7) receptors and on P2X(7) receptor-stimulated interleukin-1 beta (IL1 beta) release from THP-1 cells. The effects of the lipids were also assessed in radioligand binding studies on human P2X(7) receptors. KEY RESULTS: At concentrations (3-30 microM) below the threshold to cause cell lysis, the lipids increased agonist potency and/or maximal effects at P2X(7) receptors in both ethidium accumulation and IL1 beta release studies. There was little structure activity relationship (SAR) for this effect and sub-lytic concentrations of Triton X-100 partially mimicked the effects of the lipids. The lipids caused cell lysis and increased intracellular calcium at higher concentrations (30-100 microM) which complicated interpretation of their effects in functional studies. However, the lipids (3-100 microM) also increased agonist potency 30-100 fold in radioligand binding studies. CONCLUSIONS AND IMPLICATIONS: This study demonstrates that a diverse range of lipids increase agonist potency at the P2X(7) receptor in functional and binding studies. The broad SAR, including the effect of Triton X-100, suggests this may reflect changes in membrane properties rather than a direct effect on the P2X(7) receptor. Since many of the lipids studied accumulate in disease states they may enhance P2X(7) receptor function under pathophysiological conditions.
BACKGROUND AND PURPOSE: The P2X(7) receptor exhibits a high degree of plasticity with agonist potency increasing after prolonged receptor activation. In this study we investigated the ability of lipids to modulate agonist potency at P2X(7) receptors. EXPERIMENTAL APPROACH: A variety of lipids, including lysophosphatidylcholine, sphingosylphosphorylcholine and hexadecylphosphorylcholine were studied for their effect on P2X(7) receptor-stimulated ethidium bromide accumulation in cells expressing human recombinant P2X(7) receptors and on P2X(7) receptor-stimulated interleukin-1 beta (IL1 beta) release from THP-1 cells. The effects of the lipids were also assessed in radioligand binding studies on human P2X(7) receptors. KEY RESULTS: At concentrations (3-30 microM) below the threshold to cause cell lysis, the lipids increased agonist potency and/or maximal effects at P2X(7) receptors in both ethidium accumulation and IL1 beta release studies. There was little structure activity relationship (SAR) for this effect and sub-lytic concentrations of Triton X-100 partially mimicked the effects of the lipids. The lipids caused cell lysis and increased intracellular calcium at higher concentrations (30-100 microM) which complicated interpretation of their effects in functional studies. However, the lipids (3-100 microM) also increased agonist potency 30-100 fold in radioligand binding studies. CONCLUSIONS AND IMPLICATIONS: This study demonstrates that a diverse range of lipids increase agonist potency at the P2X(7) receptor in functional and binding studies. The broad SAR, including the effect of Triton X-100, suggests this may reflect changes in membrane properties rather than a direct effect on the P2X(7) receptor. Since many of the lipids studied accumulate in disease states they may enhance P2X(7) receptor function under pathophysiological conditions.
Authors: A D Hibell; K M Thompson; J Simon; M Xing; P P Humphrey; A D Michel Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2001-06 Impact factor: 3.000
Authors: T Haruna; M Horie; M Takano; Y Kono; H Yoshida; H Otani; T Kubota; T Ninomiya; M Akao; S Sasayama Journal: Pflugers Arch Date: 2000-12 Impact factor: 3.657
Authors: Lakshmi Ramachandra; Yan Qu; Ying Wang; Colleen J Lewis; Brian A Cobb; Kiyoshi Takatsu; W Henry Boom; George R Dubyak; Clifford V Harding Journal: Infect Immun Date: 2010-09-13 Impact factor: 3.441
Authors: A D Michel; W C Clay; S W Ng; S Roman; K Thompson; J P Condreay; M Hall; J Holbrook; D Livermore; S Senger Journal: Br J Pharmacol Date: 2008-07-28 Impact factor: 8.739
Authors: S Roman; F S Cusdin; E Fonfria; J A Goodwin; J Reeves; S C Lappin; L Chambers; D S Walter; W C Clay; A D Michel Journal: Br J Pharmacol Date: 2009-10-08 Impact factor: 8.739
Authors: Shiyuan Hong; Nicole Schwarz; Anette Brass; Michel Seman; Friedrich Haag; Friedrich Koch-Nolte; William P Schilling; George R Dubyak Journal: J Immunol Date: 2009-07-01 Impact factor: 5.422